How do you utilize anifrolumab for SLE in your practice?

The answer to this SLE question involves a complex decision-making process. It is such an important question! I apologize in advance for the long answer.

I am in the camp of achieving remission in my SLE patients and getting them off prednisone in the safest ways possible (Fanouriakis et al., PMID 3...

I think of anifrolumab particularly for patients with cutaneous disease. The TULIP-2 trial showed promise for anifrolumab in these patients as a secondary endpoint. In patients with at least moderately active skin disease, 49% of patients achieved >= 50% reduction in CLASI compared to 25% in the pla...